BLFS - バイオライフ・ソリュ―ションズ （BioLife Solutions Inc.）

Casdin Partners Master Fund LP , 10% Owner at BioLife Solns (NASDAQ: BLFS ), reported a large insider buy on May 23, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that LP purchased 74,973 shares of BioLife Solns. The total transaction amounted to $1,673,219. BioLife Solns shares are trading down 1.03% at $22.03 at the time of this writing on Wednesday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. The Importance of Insider Transactions Insider transactions shouldn''t be used … Full story available on Benzinga.com

BioLife Solutions, Inc. (NASDAQ:NASDAQ:BLFS) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ETCompany ParticipantsTroy Wichterman - CFOMichael Rice - Chairman & CEOConference…

BioLife Solutions press release (BLFS): Q1 GAAP EPS of -$0.32 misses by $0.11.Revenue of $37.7M (+4.1% Y/Y) misses by $5.24M.We remain confident that we will achieve Q4 2024 run…

Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28% Q1 2023 Adjusted gross margin improvement; 37% compared to 32% in Q4 2022 Decision to Explore Strategic Alternatives for Ultra-Low Temperature and Cryogenic Freezer…

BOTHELL, Wash., May 2, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company''s first quarter financial results…

iVexSol, a Lexington, MA-based technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), raised $23.8m in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), joined existing investors Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close […] The post iVexSol Closes $23.8M Series A-3 Financing appeared first on FinSMEs .

BioLife Solutions Inc. (NASDAQ:BLFS) closed Tuesday at $24.95 per share, up from $23.54 a day earlier. While BioLife Solutions Inc. has overperformed by 5.99%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BLFS fell by -18.46%, with highs and lows ranging from $31.12 to $10.40, whereas […]

BioLife Solutions (BLFS) reported preliminary and unaudited Q4 revenue of $44.M, an increase of 19% Y/Y, vs consensus of $43.42M

Record quarterly revenue of $44.4 million up 19% over Q4 2021 with Cell Processing Platform revenue growth of 37% Record full year revenue of $161.9 million up 36% over 2021, with organic revenue growth of 38% and Cell Processing Platform revenue growth of 53% Initial revenue guidance for…

BioLife Solutions, Inc. guidance narrowed for full-year estimates. Click here to see why we continue to rate BLFS stock as a hold.

Related Stocks: BLFS ,

BOTHELL, Wash., Nov. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company''s third quarter 2021 financial

Geode Capital Management LLC increased its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 37.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 488,006 shares of the medical equipment providers stock after acquiring an additional 133,124 shares during the quarter. Geode Capital Management LLC owned []

BioLife Solutions Inc. (NASDAQ:BLFS)s traded shares stood at 0.56 million during the last session, with the companys beta value hitting 1.47. At the close of trading, the stocks price was $53.15, to imply an increase of 4.73% or $2.4 in intraday trading. The BLFS shares 52-week high remains $60.67, putting it -14.15% down since that BioLife Solutions Inc. (NASDAQ:BLFS) Up 47.19% Since 52-Week Low; YTD Rose 33.24% Heres What You Need To Do Read More »

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Karen A. Foster sold 16,332 shares of the stock in a transaction that occurred on Monday, October 25th. The stock was sold at an average price of $44.45, for a total value of $725,957.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is []